News Search Results
Apr 01, 2025, 10:15 ET Testing, Inspection, and Certification (TIC) Market worth $282.76 billion by 2030 - Exclusive Report by MarketsandMarkets™
complexity of medical devices, pharmaceuticals, and biotechnology. Stricter regulations, like FDA guidelines and the EU MDR, are pushing the need for thorough testing and certification. Gene therapy and personalized medicine are some of the biotechnology developments requiring TIC services for safety and
More news about: MarketsandMarkets
Apr 01, 2025, 10:15 ET INTRODUCING GODDESS MAINTENANCE CO: THE NEXT BIG DISRUPTOR IN BIOTECH BEAUTY
and K18 Hair. Connaghan and Russell are acclaimed entrepreneurs known for their innovative solutions and strategic partnerships. With a focus on biotechnology, they continue to foster groundbreaking advancements in skin and hair care. Their company, Next8 Investments, aims to support emerging founders
More news about: Goddess Maintenance Co.
Apr 01, 2025, 10:03 ET DNA Data Storage Market is expected to generate a revenue of USD 6,241.39 Million by 2032, Globally, at 74.48% CAGR: Verified Market Research®
writing procedures are further accelerating market adoption. This technical advancement is promoting partnerships between storage providers and biotechnology companies. Rising Demand for Sustainable and Long-Term Storage Solutions: Conventional data storage mediums, like magnetic tapes and
More news about: Verified Market Research
Apr 01, 2025, 10:01 ET High Content Screening Market worth US$2.19 billion in 2030 with 7.5% CAGR | MarketsandMarkets™
settings. By Based on end user, the market is segmented into pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs. pharmaceutical & biotechnology companies dominated the segment in 2024 and is anticipated to grow at the highest CAGR during
More news about: MarketsandMarkets
Apr 01, 2025, 10:00 ET Yingli Pharma Announces Successful End-of-Phase 2 Meeting with FDA and Clearance of Global Multi-center Phase 3 Registration Study Design of Linperlisib for the Treatment of Relapsed and/or Refractory Peripheral T-cell Lymphoma
April 1, 2025 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma), a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune diseases, announced today that it has received clearance from the
More news about: Shanghai Yingli Pharmaceutical Co., Ltd.
Apr 01, 2025, 09:05 ET Flywheel Releases Enhanced Multimodal Functionality with Video Capabilities to Expand Research Innovation for Life Sciences
data management, automating research workflows and preparing data for AI development. Flywheel's comprehensive solution allows pharmaceutical and biotechnology companies, academic medical centers, AI developers and medical device manufacturers to realize optimum value out of their imaging data assets. For
More news about: Flywheel
Apr 01, 2025, 09:00 ET GeminiBio Expands Board with Addition of Industry Veteran
critical customer-oriented insights in the Pharma and Biotech industry. Jeffrey Gatz is a seasoned executive with extensive experience in the biotechnology and life science sectors. He spent 26 years as CEO of BioIVT, a leading global provider of biological products for life sciences and pharmaceutical
More news about: Gemini Bioproducts, LLC
Apr 01, 2025, 08:41 ET Tequity Advises Stratogent on Acquisition by PTP
harness cloud technology for strategic growth. With deep expertise in AWS, PTP delivers secure, scalable, and compliant solutions tailored to the biotechnology industry. About Tequity Tequity Advisors advises enterprise B2B SaaS, Cloud, and IT companies on strategic M&A to drive
More news about: Tequity Advisors
Apr 01, 2025, 08:05 ET Avantor® Showcases Scalable Fluid Handling Innovations at INTERPHEX
for the life sciences and advanced technology industries, announces its presence at INTERPHEX, the premier annual gathering of pharmaceutical, biotechnology, and device development and manufacturing professionals. The company will showcase fluid handling technologies that support every step of the bioprocessing
More news about: Avantor and Financial News
Apr 01, 2025, 08:00 ET Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the Jones Las Vegas Healthcare and Technology Innovation
More news about: Anixa Biosciences, Inc.
Apr 01, 2025, 08:00 ET Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease
Sana Biotechnology (NASDAQ: SANA),
More news about: Flagship Pioneering
Apr 01, 2025, 07:00 ET Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team
Laura Shawver Laura is a pioneer in healthcare who brings over two decades of leadership experience in biotechnology and patient advocacy, creating new paradigms in research and treatment for cancer and other serious diseases. As a scientist, she conducted research
More news about: Adcendo
Apr 01, 2025, 07:00 ET Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team
Laura Shawver Laura is a pioneer in healthcare who brings over two decades of leadership experience in biotechnology and patient advocacy, creating new paradigms in research and treatment for cancer and other serious diseases. As a scientist, she conducted research
More news about: Adcendo
Apr 01, 2025, 06:30 ET Immunic, Inc. to Participate in Scientific and Industry Conferences in April
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
Apr 01, 2025, 06:00 ET IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events
Executive Officer and Darrin Beaupre, Chief Medical Officer, hosted by Gregory Renza, M.D., Director and Senior Biotechnology Research AnalystStifel 2025 Virtual Targeted Oncology ForumTuesday, April 8th,
More news about: IDEAYA Biosciences, Inc.
Apr 01, 2025, 05:45 ET Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sana Biotechnology, Inc.(SANA) Shareholders
April 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Apr 01, 2025, 05:45 ET ICON Public Limited Company Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 11, 2025 to Discuss Your Rights - ICLR
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Levi & Korsinsky, LLP
Apr 01, 2025, 05:00 ET Plant Biotechnology Market worth $76.79 billion by 2030- Exclusive Report by MarketsandMarkets™
biopesticides sub-segment hold the significant market share in the crop protection & nutrition solutions segment for plant biotechnology. Advances in plant biotechnology have contributed significantly towards the development of biopesticides. Such developments as RNA interference (RNAi) technology
More news about: MarketsandMarkets
Mar 31, 2025, 16:30 ET Carisma Therapeutics Provides Corporate Updates
and prepare for a potential wind-down of operations, if necessary.About Carisma Therapeutics Carisma Therapeutics is a biotechnology Company pioneering macrophage engineering to develop groundbreaking therapies for fibrosis and cancer. With a strong commitment to patient-centric
More news about: Carisma Therapeutics Inc.
Mar 31, 2025, 16:15 ET Thunder Power Holdings, Inc. Announces Financial Results and Strategic Developments
Nasdaq Capital Market benefits smaller companies focused on raising capital and lists a wide variety of companies, including those from technology, biotechnology, and other sectors. "We believe listing on the Nasdaq Capital Market is more reflective of AIEV at this stage in our development, allowing
More news about: Thunder Power Holdings, Inc.
Mar 31, 2025, 12:43 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
March 31, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officers. The class action, filed in the United States
More news about: Pomerantz LLP
Mar 31, 2025, 10:15 ET Clinical Trial Supplies Market worth $8.18 billion in 2030 with 8.9% CAGR | MarketsandMarkets™
sourcing of comparator drugs. By end users, the market is segmented into pharmaceutical & biotechnology companies, CROs & CDMOs and Other end users. Pharmaceutical & biotechnology companies dominated the segment in 2024 and is anticipated to grow at the highest significant CAGR during
More news about: MarketsandMarkets
Mar 31, 2025, 09:59 ET Crown Laboratories Now Operates Under the Name Revance
change marks a significant milestone in the company's strategic transformation following its recent acquisition of Revance Therapeutics, Inc., a biotechnology company known for its cutting edge innovation in aesthetics and therapeutics, which joins Crown's deep roots in science-driven brands for skin health
More news about: Crown Laboratories, Inc.
Mar 31, 2025, 09:30 ET ICLR Deadline: ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
were insufficient to shield ICON from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: THE ROSEN LAW FIRM, P. A.
Mar 31, 2025, 08:30 ET Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications
commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.